Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease

Mult Scler. 2023 Feb;29(2):270-276. doi: 10.1177/13524585221134214. Epub 2022 Dec 1.

Abstract

Background and objective: Myelin-oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) frequently initiates during childbearing years. This study investigated the impact of pregnancy and post-partum on MOGAD activity.

Methods: Retrospective analysis of clinical and demographic data from a multicenter French cohort of adult patients with MOGAD. All adult female patients who had a pregnancy after disease onset or in the year before disease onset were included. The annualized relapse rate was evaluated in patients who had a pregnancy after disease onset, to evaluate the impact of pregnancy and post-partum on MOGAD course.

Results: Twenty-five informative pregnancies after disease onset were identified. No relapse was recorded during these pregnancies and only three relapses occurred during the first 3 months post-partum. The annualized relapse rate decreased from 0.67 (95% confidence interval: 0.40-1.10) during the pre-pregnancy period to 0 (95% confidence interval: 0-0.21) during pregnancy and to 0.22 (95% confidence interval: 0.09-0.53) during the first year post-partum. Among 144 female patients in their childbearing age recorded in the database, 18 (12.5%) reported their first symptoms during pregnancy or in the 12 months post-partum.

Discussion: Our study suggests a marked reduction of MOGAD relapse rate during pregnancy and the post-partum period. Prospective studies on the role of pregnancy and delivery in MOGAD course are needed.

Keywords: MOGAD; postpartum; pregnancy; relapse rate.

Publication types

  • Multicenter Study

MeSH terms

  • Autoantibodies*
  • Female
  • Humans
  • Myelin-Oligodendrocyte Glycoprotein
  • Postpartum Period*
  • Pregnancy
  • Prospective Studies
  • Recurrence
  • Retrospective Studies

Substances

  • Myelin-Oligodendrocyte Glycoprotein
  • Autoantibodies